Benzinga | Feb 19, 2021 10:32AM EST

FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease

* Under Priority Review status, the FDA has accepted Incyte Corporation's (NASDAQ: INCY) marketing application for review seeking approval for ruxolitinib cream.

* Ruxolitinib is a selective JAK1/JAK2 inhibitor as a treatment for atopic dermatitis, a type of eczema characterized by inflammation and intense itch.

* The company has submitted a Priority Review Voucher (PRV) along with the application for ruxolitinib cream. The use of the PRV shortens the review period by four months. The agency's action date is June 21.

* Price Action: INCY increased 0.55% at $82 on last check Friday.